MAIA Biotechnology, Inc.
$1.38
-$0.02 (-1.51%)
$1.36Day Range$1.45
Key Statistics
Market Cap
$85.17M
Shares Outstanding
60.8M
Primary Exchange
XASE
Currency
USD
Type
CS
IPO Date
Jul 28, 2022
Round Lot
100
Locale
US
Trading Data
Day Open
$1.44
Day High
$1.45
Day Low
$1.36
Volume
515.8K
VWAP
$1.40
Prev Close
$1.40
Transactions
--
Acc. Volume
--
About MAIA Biotechnology, Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.
PHARMACEUTICAL PREPARATIONSSIC 283413 employees444 WEST LAKE STREET, SUITE 1700, CHICAGO, IL, 60606312-416-8592IPO Jul 28, 2022US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001878313
- Composite FIGI
- BBG0113Q7J88
- Share Class FIGI
- BBG0113Q7J97
- Ticker Root
- MAIA
- SIC Code
- 2834
About MAIA Biotechnology, Inc. (MAIA) Stock
MAIA Biotechnology, Inc. (MAIA) closed the 2026-09-17 session at $1.38, down 1.51% versus the previous close (-0.02). The stock opened at $1.44 and traded between $1.36 and $1.45 during that session. Session trading volume was 516K shares. The volume-weighted average price (VWAP) is $1.40.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.
MAIA Biotechnology, Inc. has a market capitalization of $85.2 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. MAIA is listed on the XASE exchange. The company employs approximately 13 people. MAIA Biotechnology, Inc. is headquartered in CHICAGO, IL. The recorded listing date is 2022-07-28.
On this page you can find market MAIA stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.